Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... LayerBio is an MIT spin-off developing novel drug ... Eye Institute (NEI) at the National Institutes of Health ... to develop a drug-eluting intraocular lens (IOL) for cataract ... vision loss in people over age 40 and the ... Mandell, LayerBio’s Founder and CEO, "There is a critical ...
    (Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
    (Date:12/19/2014)... MILLBROOK, N.Y. , Dec. 18, 2014 Egenix, ... has been elected Chairman of the Board, to succeed ... President and CEO, but will continue as a member of ... that he has added to the company over almost twenty ... The Board of Directors has established a Search ...
    (Date:12/17/2014)... Based on the revenues gained from ... is dominated by four major players contributing to ... players include GE Healthcare (U.K.), Siemens AG (Germany), ... Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , ... attributed to its strong product portfolio, which includes ...
    Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
    ... in a lab dish to the steroid DHEA, exhibit a ... play a role in helping the brain produce new cells, ... online editions of the Proceedings of the National Academy of ... of scientists at the University of Wisconsin-Madison, provides some of ...
    ... , a data quality solutions provider, announced today ... Information Quality Suite to work with Oracle Warehouse ... intelligence integration design tool that manages data lifecycles. ... intelligence application and customize the way data quality ...
    ... Inc. announced Tuesday that its genetic analysis ... chromosomal analysis, opening a new market to the ... extension of the Invader technology, Madison-based Third Wave ... (ASRs) for prenatal chromosomal analysis to the University ...
    Cached Biology Technology:DHEA Boosts Growth Rate of Human Neural Stem Cells 2DHEA Boosts Growth Rate of Human Neural Stem Cells 3
    (Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
    (Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
    (Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
    Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
    ... M.D., director of the National Institute of Allergy and Infectious ... been awarded the 2007 Mary Woodard Lasker Award for Public ... health programs, in AIDS and biodefense. The award will be ... New York City. , Dr. Fauci is honored for his ...
    ... in conjunction with the National Evolutionary Synthesis Center, will ... 1, 2007, at the Hyatt Regency Hotel in Atlanta, ... and Populations, is part of the 2007 Professional Development ... The aim of the symposium is ...
    ... National Institutes of Health has awarded one of 12 ... a team based at the University of Chicago Medical ... 2006, form the core of an NIH effort to ... "transform how clinical and translational research is conducted," ultimately ...
    Cached Biology News:Anthony S. Fauci awarded Lasker Award for Public Service 2Anthony S. Fauci awarded Lasker Award for Public Service 3Anthony S. Fauci awarded Lasker Award for Public Service 4AIBS to cohost symposium on evolution, disease and human health 2AIBS to cohost symposium on evolution, disease and human health 3AIBS to cohost symposium on evolution, disease and human health 4NIH awards nearly $23M to University of Chicago for translational research 2NIH awards nearly $23M to University of Chicago for translational research 3NIH awards nearly $23M to University of Chicago for translational research 4